Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) is one of the Oversold Growth Stocks to Buy According to Analysts. Wall Street has a mixed opinion on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) since the company released its fiscal second quarter 2025 results. The company posted $178.49 million in revenue, down 10.61$10.15 million. On the bright side, the EPS of negative $0.33 topped estimates by$0.15. Management noted that they are proud of the FDA approval of EMPA ...